Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study
Keyword(s):
Phase I
◽
Results of a phase I dose escalation study in the treatment of inoperable non-small cell lung cancer
2003 ◽
Vol 57
(2)
◽
pp. S417-S418
◽
Keyword(s):
Phase I
◽
2016 ◽
Vol 8
(10)
◽
pp. E1287-E1292
◽